The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 70, Issue 3, 2009, Pages 318-325

  Meyer, Jonathan M ^a,d   Rosenblatt, Lisa C ^b   Kim, Edward ^b   Baker, Ross A ^b   Whitehead, Richard ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGRO; OBESITY; PREDICTION; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; ACUTE DISEASE; AFRICAN AMERICAN; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ETHNOLOGY; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ACUTE DISEASE; ADULT; AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 64149088458     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04267     Document Type: Article

References (49)

1. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1-2):21-28
2. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-157 (Pubitemid 40812332)
3. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22 (Pubitemid 44234064)
4. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am 2007;91(6):1169-1184 (Pubitemid 350010914)
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497
6. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37(12):1595-1607
7. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 2007;91(6):1063-1077 (Pubitemid 47625441)
8. Assmann G, Guerra R, Fox G, et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol 2007;99(4):541-548 (Pubitemid 46215539)
9. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30(1):8-13
10. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-2650 (Pubitemid 41785063)
11. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005;51(6):931-938 (Pubitemid 40740871)
12. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80(1):19-32 (Pubitemid 41587460)
13. Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007;191:23-29 (Pubitemid 47035177)
14. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
15. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65(2):267-272
16. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334-1349 (Pubitemid 38989085)
17. van Nimwegen LJ, Storosum JG, Blumer RM, et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008;93(2):572-577
18. Fujimoto WY, Bergstrom RW, Boyko EJ, et al. Susceptibility to development of central adiposity among populations. Obes Res 1995;3(suppl 2):179S-186S
19. Haffner SM, D'Agostino R, Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45(6):742-748
20. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US Diabetes Care 2005;28(11):2745-2749
21. Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis 2007;17(1):143-152 (Pubitemid 46231378)
22. Ananth J, Kolli S, Gunatilake S, et al. Atypical antipsychotic drugs, diabetes and ethnicity. Expert Opinion on Drug Safety 2005;4(6):1111-1124 (Pubitemid 41671607)
23. Herbeck DM, West JC, Ruditis I, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 2004;55(6):677-684 (Pubitemid 38720859)
24. Mallinger JB, Fisher SG, Brown T, et al. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006;57(1):133-136 (Pubitemid 43053850)
25. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64 (Pubitemid 34538833)
26. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22(7):841-852 (Pubitemid 34743435)
27. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Safety 2007;30(7):589-599 (Pubitemid 47037318)
28. de Leon J, Diaz FJ, Josiassen RC, et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol 2007;27(1):22-27 (Pubitemid 46105759)
29. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008;101(1-3):273-286
30. Ader M, Garvey WT, Phillips LS, et al. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res 2008;42(13):1076-1085
31. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-389 (Pubitemid 34680462)
32. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137-140 (Pubitemid 34626163)
33. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56
34. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27(10):2444-2449 (Pubitemid 39281399)
35. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007;164(8):1181-1188 (Pubitemid 47292406)
36. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology 2004;174(4):477-489 (Pubitemid 39119337)
37. Campbell DB, Ebert PJ, Skelly T, et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry 2008;63(1):32-41 (Pubitemid 350234888)
38. Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res 2006;86(1-3):99-109 (Pubitemid 44234039)
39. Tamayo JM, Mazzotti G, Tohen M, et al. Outcomes for Latin American versus white patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol 2007;27(2):126-134 (Pubitemid 46603546)
40. Sumner AE, Finley KB, Genovese DJ, et al. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005;165:1395-1400 (Pubitemid 40973422)
41. Tupper T, Gopalakrishnan G. Prevention of diabetes development in those with the metabolic syndrome. Med Clin North Am 2007;91(6):1091-1105 (Pubitemid 47628857)
42. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32(2):289-297 (Pubitemid 46106936)
43. Buckley PF, Miller DD, Singer BE, et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005;79:281-288 (Pubitemid 41457268)
44. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006;18(1):23-31
45. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006;51(8):502-511 (Pubitemid 44166338)
46. Wu R-R, Zhao J-P, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299(2):185-193
47. Meyer JM, Pandina G, Bossie CA, et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27(12):1930-1941 (Pubitemid 43293215)
48. Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007;27(4):365-368 (Pubitemid 47075507)
49. Weiden PJ, Newcomer JW, Loebel A, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985-994